Hepatocellular carcinoma recurrence after directly acting antivirals

Early versus late start of directly acting antivirals regarding hepatocellular carcinoma recurrence : A randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201708002452985

Enrollment

Registered

2017-07-21

Start date

2017-08-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C virus, Hepatocellular carcinoma

Interventions

late initiation of antivirals for HCV

Early initiation of Antivirals for HCV

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1- Child-Pugh class is A or B. 2- With either single HCC lesion less than 5 cm or ¿ 3 lesions less than 3 cm. 3- total ablation of Hcc lesion(s) using radiofrequency or microwave ablation.

Exclusion criteria

Exclusion criteria: 1-Positive HBsAg. 2-History of alcohol consumption 3-Patients with other known causes of chronic liver disease. 4-Patients who have received previous locoregional treatment for HCC. 5-Patients with previous exposure to directly acting antivirals for hepatitis C virus.

Design outcomes

Primary

Measure	Time frame
sustained virological response;rate of hepatocellular carcinoma recurrence after antiviral therapy for HCV	—

Secondary

Measure	Time frame
Changes in Child Pugh score, MELD score and performance status.	—

Countries

Egypt

Contacts

Public ContactAhmed Kamal

Assistant lecturer

ahmed.kamal.med.scientific@gmail.com+201279734654

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026